Danske Bank A S Acquires New Stake in DexCom, Inc. $DXCM

Danske Bank A S bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 195,049 shares of the medical device company’s stock, valued at approximately $13,137,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Reflection Asset Management acquired a new position in DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors purchased a new stake in DexCom during the first quarter worth about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom during the fourth quarter worth about $32,000. Wellington Grp LLC lifted its position in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares in the last quarter. Finally, DV Equities LLC purchased a new position in shares of DexCom in the fourth quarter valued at approximately $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the sale, the director directly owned 48,852 shares of the company’s stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,035 shares of company stock valued at $5,446,673 over the last quarter. Company insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on DXCM. Argus lifted their price objective on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Barclays reiterated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. BTIG Research reissued a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price target on shares of DexCom in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. boosted their price target on shares of DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Stock Up 0.4%

DXCM stock opened at $90.22 on Friday. The company’s 50 day moving average price is $77.15 and its 200 day moving average price is $70.79. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $91.96. The firm has a market capitalization of $34.05 billion, a price-to-earnings ratio of 35.66, a PEG ratio of 1.52 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.